Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
about
A comprehensive review on metabolic syndromeOxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic 'eat-me' signals: cleavage and inhibition of phagocytosis by Lp-PLA2Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesLipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complicationsIdentifying novel biomarkers for cardiovascular disease risk predictionAntioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a reviewGenome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study.Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literatureNitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NFκB pathwaysAssociation of carotid plaque Lp-PLA(2) with macrophages and Chlamydia pneumoniae infection among patients at risk for stroke.Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and CaucasiansReplacing with whole grains and legumes reduces Lp-PLA2 activities in plasma and PBMCs in patients with prediabetes or T2D.Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemiaPlasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor.Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisAssociations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke.Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional studyEffect of Pitavastatin Treatment on ApoB-48 and Lp-PLA₂ in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome.The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA₂.Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients.Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.Pleiotropic effects of niacin: Current possibilities for its clinical use.Platelet activating factor: A potential biomarker in acute coronary syndrome?Resveratrol suppresses lipoprotein-associated phospholipase A2 expression by reducing oxidative stress in macrophages and animal models.Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-α) and their relation to premature atherosclerosis in β-thalassemia children.Effects of Pu-erh tea aqueous extract (PTAE) on blood lipid metabolism enzymes.The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: A systematic review and meta-analysis.Elevated 20-HETE in metabolic syndrome regulates arterial stiffness and systolic hypertension via MMP12 activation.Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells
P2860
Q21284500-74807A11-541B-42D2-A6DC-D6E8591F3E31Q23923069-8411BAFE-1470-4460-A309-A7F7D34C2536Q24289511-CD80C39F-30D2-4088-8C55-1E5AD4E09E55Q26777871-A3E92A3D-2302-4C6C-9DC1-ADFB9D69F240Q26865722-68B08F19-BF5D-448B-99A2-4E54E1EB69F1Q26991853-D38C3D8A-76E0-4548-BCAF-C7CEB2CA3240Q30484496-BB9DA9E3-1B93-43DC-88B0-859EBFF4D626Q33536648-478AC1FB-8A40-4092-9243-713A589CF28DQ33585468-94457165-A620-4956-BAA5-5E3E07C27463Q33602983-D108ACEE-5345-4047-B2E0-EE2587E78281Q33849524-53260BC1-307A-4D60-BFBA-CE54EC9D41EFQ33945132-CF1A802B-280C-4629-AB1F-A2FDB0620A9FQ34188093-71F29F7A-28D7-4B37-8DD7-BA687012BD36Q34541071-4B4BB054-24D0-47B4-ACC3-8EF93A0D1225Q35674514-A7BC34A1-B631-4CEF-B49A-732410F5CF48Q35764402-FE0DEF3B-958D-480C-8069-F64EDDB99D44Q36524201-461ED1CA-6B18-4776-B966-89FB4762E68EQ36707842-5B2D9A05-BFC0-438D-A23D-B18AA4A700B2Q36716991-2BA7972D-2B28-4916-860C-92FDC730DA2BQ37305388-2D78BD07-5E6A-409A-98EE-FBE718C32400Q37554151-E7C1C93C-BA48-497F-AB9D-7BFA4CD3BB19Q37991749-44B9DD6A-7D5A-4F51-9430-9C097E4F9B82Q38810790-70E036FE-C0A7-451F-BEEC-F75E89AE9037Q38993442-0D0DFA59-4C74-4B40-8B3F-34CD52AF8070Q46352015-0E9C1910-34F7-4371-B980-F9416F2D32C0Q46590378-E994BFF7-F084-40D5-8E11-35929F943980Q47408449-EF0E5406-142A-4350-BB82-3BD7EF64FC00Q49485993-E1C1FD50-6D97-4E1A-BE46-0641647995B8Q50081720-77E031C9-C5AF-485C-88B3-3165F2192EACQ56974269-884E19D6-5673-4A73-BFD0-7DFFD632E1E9
P2860
Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Lipoprotein-associated phospho ...... esults from the Bruneck study.
@en
type
label
Lipoprotein-associated phospho ...... esults from the Bruneck study.
@en
prefLabel
Lipoprotein-associated phospho ...... esults from the Bruneck study.
@en
P2093
P50
P356
P1476
Lipoprotein-associated phospho ...... esults from the Bruneck study.
@en
P2093
Christian J Wiedermann
Georg Egger
Johann Willeit
Marlene Notdurfter
Michael Knoflach
Stefan Kiechl
P304
P356
10.1093/EURHEARTJ/EHN502
P577
2008-11-19T00:00:00Z